2024-512388-29-00招募中3 期
A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients undergoing complex cardiac surgery (involving CPB)
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 124
- 试验地点
- 13
- 主要终点
- The primary efficacy endpoint is the number of units of allogeneic blood products (RBC plus FFP plus platelet concentrate) given to patients between randomization and 24 hours thereafter.
研究概览
简要总结
The primary objective of the study is to evaluate the efficacy of FGTW in combination with Standard of care in reducing the need for allogeneic transfusions within the first 24 hours after randomization in complex cardiac surgery patients.
研究设计
- 分配方式
- Randomized
- 主要目的
- Follow-up
- 盲法
- Double (Analyst, Monitor, Investigator, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Male or female adult patients ≥18 years
- •Patients undergoing a planned complex cardiac surgery procedure involving CPB, including reoperation and/or complex surgical procedures. Complex surgical procedures are defined as any procedure other than first time isolated coronary artery bypass grafting (CABG), single valve repair/replacement and repair of atrial septal defect (ASD). This criterion represents the main eligibility criterion and so used in the definition of the full analysis set.
- •With a FIBTEM MCF ≤10 mm during the last 20 minutes of CPB.
- •Patients requiring an IMP dose ≤8 g calculated with the formula based on patient's weight and the value of FIBTEM MCF
- •Signed and dated informed consent form (ICF)
- •Willingness to comply with all study procedures and availability for the duration of the study
- •Covered by healthcare insurance in accordance with local requirements
- •FIBTEM MCF ≤14 mm during the screening period prior to the surgery. FIBTEM MCF is the recommended test, for consistency with end of CPB FIBTEM MCF. Fibrinogen concentration (Clauss method) may be substituted, with fibrinogen level ≤3 g/L. Note: the objective of this criterion is to allow to screen fail patients unlikely to meet inclusion criterion #3 prior to surgery rather than at the end of CPB and reduce the patient’s and site’s constraints of continuing the screening process throughout surgery. However, a patient with a preoperative FIBTEM MCF > 14 mm (or plasma fibrinogen > 3 g/L) can, under exceptional circumstances, continue to be screened until FIBTEM MCF measurement during the last 20 minutes of CPB, if, in the investigator’s judgement, the patient is considered at high risk of clinically significant bleeding (e.g., complex multiple procedures or an expected very long duration - several hours - of CPB).
排除标准
- •Heart transplantation
- •Excessive hemodilution with hematocrit (Ht) <22% in men and women at the time of taking sample for FIBTEM MCF during the last 20 minutes of CPB
- •Congenital coagulation deficiencies (von Willebrand disease, factor V Leiden, Protein C deficiency, cryoglobulinemia, antiphospholipid syndrome…)
- •Any known thromboembolic disorder
- •Female of reproductive potential not using effective contraception (condoms; occlusive caps with spermicide; injectable, patch, or combined oral estro-progestative or progestative contraceptives; depot intramuscular medroxyprogesterone; or subcutaneous implants of progestative contraceptive implants) for at least one month prior to screening
- •Known pregnancy or positive blood pregnancy test for women of childbearing potential and/or breast-feeding women
- •Participation in another clinical study involving an investigational medicinal product within 30 days prior to screening or or 5 half-lives of this investigational medicinal product, whichever is longer, or concomitantly with this study
- •Treatment with any fibrinogen concentrate and/or fibrinogen containing product within 32 days prior to infusion of FGTW
- •Previous cardiac surgical procedure within three months before randomization
- •Evidence or suspicion of infection (fever >38.5°C and white blood cell count >11/mm3)
- •Active endocarditis
- •Repair of complex congenital abnormalities
- •Emergency surgery, patients in cardiogenic shock, or expected mortality within 24 hours of surgery
- •Pre-existing thrombocytopenia with platelet count < 150 000/ mm3
- •Any known pulmonary, hepatic, or renal disease or any other major concomitant significant medical condition that might interfere with treatment evaluation according to the Investigator's judgment
- •Known hypersensitivity or other severe reaction to any component of the IMP
- •Patients at high risk of thrombotic events unable to stop prophylactic low-molecular-weight heparin (LMWH) 12 hours and fondaparinux 24 hours before surgery (longer interval in case of impaired renal function)
- •Patients unable to stop treatment by vitamin K antagonists 3-5 days before surgery to obtain an international normalized ratio (INR) <1.5
- •Patients unable to stop treatment by direct oral anticoagulant at least 48 hours before surgery (except aspirin)
- •Patients unable to stop treatment by P2Y12 inhibitors before surgery (discontinuation duration before surgery: ticagrelor 3 days, clopidogrel 5 days, and prasugrel 7 days) [30]
- •Severe anemia with hemoglobin (Hb) ≤10 g/dL
结局指标
主要结局
The primary efficacy endpoint is the number of units of allogeneic blood products (RBC plus FFP plus platelet concentrate) given to patients between randomization and 24 hours thereafter.
The primary efficacy endpoint is the number of units of allogeneic blood products (RBC plus FFP plus platelet concentrate) given to patients between randomization and 24 hours thereafter.
次要结局
- Blood drainage volume within 12 hours after randomization
- Percentage of patients with total avoidance of allogeneic transfusions within 24 hours after randomization
- Number of transfusion units infused between 24 hours after randomization and the hospital discharge for each class of allogeneic blood product (RBC, FFP, and platelet concentrate)
- Volume of transfusion units infused between 24 hours after randomization and the hospital discharge for each class of allogeneic blood product (RBC, FFP, and platelet concentrate)
- Number of pre-donated autologous RBC concentrate units, RBC concentrate prepared by cell-saver, colloids, and crystalloids after randomization
- Percentage of patients with surgical re-exploration for bleeding within 24 hours after randomization
- Mortality at 24 hours, 7 days, and 30 days after randomization
- Percentage of patients with each surgical morbidity at 24 hours, 7 days, and 30 days after randomization (see Section 9.2.8)
- Percentage of patients with post-surgery stage 1 AKI (with increase in creatinine by >50% from baseline until hospital discharge)
- Percentage of patients with fibrinogen concentration below the LLN from visit 2 to visit 5
- Percentage of patients receiving aPCC/PCCs, rFVIIa, cryoprecipitate or additional FC as rescue therapy within 24 hours after randomization
- Duration of hospitalization
- Length of stay in ICU
研究者
LFB Medical Information
Scientific
LFB-Biotechnologies
研究点 (13)
Loading locations...
相似试验
已完成
3 期
Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne VulgarisAcne VulgarisNCT03717506Balmoral Medical company1,236
已完成
2 期
Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)AdenocarcinomaNCT00661830PD Dr Markus Möhler103
已完成
3 期
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HumiraPlaque Type PsoriasisNCT02016105Sandoz465
已完成
2 期
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung DiseaseCystic FibrosisNCT00103714Merck Sharp & Dohme LLC72
Unknown
3 期
Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02089126LG Life Sciences230